George Fennell reported a change in beneficial ownership of IDEXX Laboratories Inc. common stock on June 1, 2026, tied to the vesting of restricted stock units. The filing describes an equity event involving 10,717 shares of IDEXX common stock, with the shares listed at $284 per share. According to the explanatory footnote, each restricted stock unit represented a contingent right to receive one share of IDEXX common stock, and the RSUs vested in a single installment on June 1, 2026. As a result, the vesting converted the RSU rights into shares on a one-for-one basis. The document identifies the security as IDEXX common stock and notes that the RSU-related action was not subject to an expiration date, with the footnote stating “not applicable.” The provided text does not show a specific Form 4 transaction code or Fennell’s total beneficial ownership after the transaction, so those details cannot be determined from the filing excerpt. The report was signed on June 2, 2026, by Lily J. Lu as attorney-in-fact for George Fennell. The transaction matters because it reflects the vesting of previously awarded equity compensation, increasing or confirming Fennell’s direct exposure to IDEXX common stock through shares delivered upon settlement of RSUs.